A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort
Discontinuation rates of CD20Mabs were low, and the most common reason for stopping was side effects. Although not designed for comparison, our study suggests RMS patients may persist longer on OCR than RTX.
Authors
- Robert Carruthers (ORCID: https://orcid.org/0000-0001-7085-1001)
- Dian Kuipers
- David Jure Hunt (ORCID: https://orcid.org/0000-0003-0842-7538)
- Nathan Chu (ORCID: https://orcid.org/0000-0001-8721-1174)
- Christopher Uy (ORCID: https://orcid.org/0000-0002-0688-6522)
- Kyra West
- Alice Schabas (ORCID: https://orcid.org/0000-0002-5925-1715)
- Virginia Devonshire (ORCID: https://orcid.org/0000-0002-8512-7590)
- Mohammad Salem Alhalabi
- Jomana Morkous
- Ana-Luiza Sayao
- Anthony Traboulsee
Institutions
- University of British Columbia (CA)
- University of Alberta (CA)
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1017/cjn.2025.10520
- Citations
- 1
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 39.15